Honokiol, a well-tolerated
natural product, can inhibit the proliferation of
cancer cells. But its water insolubility hampers its systemic administration for
therapy of
cancer. As a drug delivery system, the pegylated
liposome (
PEGL) can increase the water solubility and targeting of the
drug.
Honokiol has been successfully encapsulated by
PEGL in our laboratory. We wondered whether the combination treatment with pegylated
liposomal honokiol (H-
PEGL) and
cisplatin (DDP) could improve the antitumor efficacy in ovarian
carcinoma. H-
PEGL could introduce apoptosis of SKOV3 cells in vitro, which was quantified by flow cytometric analysis, and the cellular morphologic changes were determined by
propidium iodide staining. In a human ovarian
carcinoma mouse model, combination treatment with H-
PEGL (0.4 mg/day for 30 days; intraperitoneal) and DDP (5 mg/kg on days 7, 11, 15, 19; intraperitoneal) acted synergistically to inhibit
tumor growth by 91.48% without notable toxicity, but H-
PEGL and DDP alone only inhibit
tumor growth by 66.83% and 52.5% as compared to the NaCl
solution control, respectively. Assessment of microvessel density and apoptosis index by CD31 and
terminal deoxynucleotidyl transferase-mediated nick end labeling immunohistochemistry respectively suggested that the antitumor activity of H-
PEGL is mediated by angiogenesis inhibition and introduction of apoptosis. Our results showed us a splendid prospect of the clinical application of combination treatment on patients suffering from
ovarian cancer with H-
PEGL and DDP.